Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:6354 |
Name | chronic lymphocytic leukemia/small lymphocytic lymphoma |
Definition | A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia chronic lymphocytic leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | Ibrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Ibrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Rituximab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Rituximab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Idelalisib + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Idelalisib + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
TP53 mutant | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
TP53 loss | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Obinutuzumab + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Acalabrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Acalabrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Duvelisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Duvelisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Zanubrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | predicted - sensitive | detail... |
TP53 loss | Acalabrutinib + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Acalabrutinib + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Alemtuzumab + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Alemtuzumab + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Methylprednisolone + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Methylprednisolone + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Idelalisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Idelalisib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Lenalidomide + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Lenalidomide + Rituximab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Zanubrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Pirtobrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Pirtobrutinib | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Methylprednisolone + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Methylprednisolone + Obinutuzumab | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 loss | Ibrutinib + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
TP53 mutant | Ibrutinib + Venetoclax | chronic lymphocytic leukemia/small lymphocytic lymphoma | sensitive | detail... |
ATM mutant | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
TP53 loss TP53 mut | N/A | chronic lymphocytic leukemia/small lymphocytic lymphoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT01125176 | Phase II | Lenalidomide + Rituximab + Thalidomide | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL | Completed | USA | 0 |
NCT01253460 | Phase II | Cyclophosphamide Rituximab + Sapacitabine | Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) | Terminated | USA | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 2 |
NCT01804686 | Phase III | Ibrutinib | A Long-term Extension Study of PCI-32765 (Ibrutinib) | Enrolling by invitation | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 10 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01886859 | Phase I | Ibrutinib + Lenalidomide | Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Completed | USA | 0 |
NCT01976585 | Phase Ib/II | CDX-301 + Poly ICLC | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Completed | USA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02005289 | Phase II | Lenalidomide + Tafasitamab-cxix Ibrutinib + Tafasitamab-cxix | Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL | Active, not recruiting | USA | 0 |
NCT02006485 | Phase I | Ublituximab + Umbralisib Ibrutinib | Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies | Completed | USA | 0 |
NCT02007044 | Phase II | Ibrutinib Ibrutinib + Rituximab | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02029443 | Phase Ib/II | Acalabrutinib | ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ITA | GBR | 0 |
NCT02160015 | Phase I | Ibrutinib + Lenalidomide + Rituximab | Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02254772 | Phase Ib/II | Ipilimumab + SD-101 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Completed | USA | 0 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT02296918 | Phase I | Acalabrutinib + Obinutuzumab | ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL | Active, not recruiting | USA | 0 |
NCT02329847 | Phase Ib/II | Ibrutinib + Nivolumab | Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | Completed | USA | TUR | POL | ISR | ESP | AUS | 0 |
NCT02337829 | Phase II | Acalabrutinib | ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | Active, not recruiting | USA | 0 |
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02381080 | Phase I | Erythromycin + Ibrutinib + Voriconazole | Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy | Completed | ESP | CAN | 1 |
NCT02384954 | Phase Ib/II | Nogapendekin alfa inbakicept + Rituximab | ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab | Terminated | USA | 0 |
NCT02406742 | Phase Ib/II | Obinutuzumab Rituximab Ibrutinib CC-122 | A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE) | Completed | USA | ITA | ESP | DEU | AUT | 0 |
NCT02420912 | Phase II | Ibrutinib + Nivolumab | Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Terminated | USA | GBR | FRA | 0 |
NCT02514083 | Phase II | Fludarabine + Ibrutinib | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | Active, not recruiting | USA | 0 |
NCT02518555 | Phase II | Ibrutinib | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02556931 | Phase II | Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | Completed | USA | 0 |
NCT02576275 | Phase III | Bendamustine + Rituximab Duvelisib | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) | Withdrawn | USA | 0 |
NCT02614508 | Phase I | Buparlisib + Ibrutinib Buparlisib + Ofatumumab | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT02626455 | Phase III | Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) | Terminated | USA | TUR | SVK | ROU | POL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 13 |
NCT02629809 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT02639910 | Phase II | Tafasitamab-cxix + Venetoclax Idelalisib + Tafasitamab-cxix | Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS) | Completed | USA | POL | ITA | GBR | DEU | AUT | 0 |
NCT02640209 | Phase I | CART19 cells | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |
NCT02640833 | Phase I | Duvelisib + Venetoclax | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | Withdrawn | USA | 0 |
NCT02662296 | Phase II | Idelalisib Ibrutinib | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Withdrawn | USA | 0 |
NCT02677948 | Phase Ib/II | Ibrutinib + Pacritinib | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Withdrawn | USA | 0 |
NCT02722668 | Phase II | Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | Active, not recruiting | USA | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02756897 | Phase II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | 0 |
NCT02787369 | Phase I | Idelalisib + Ricolinostat Ibrutinib + Ricolinostat | ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | Active, not recruiting | USA | 0 |
NCT02825836 | Phase Ib/II | TL-895 | Phase I/II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma | Active, not recruiting | USA | POL | ITA | HUN | GBR | 2 |
NCT02846623 | Phase II | Atezolizumab + Obinutuzumab + Venetoclax | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | Recruiting | USA | 0 |
NCT02867618 | Phase Ib/II | Carfilzomib + Umbralisib | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | Terminated | USA | 0 |
NCT02900716 | Phase I | DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | Completed | USA | 0 |
NCT02910583 | Phase II | Ibrutinib Ibrutinib + Venetoclax | Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Completed | USA | POL | NZL | ITA | ESP | AUS | 0 |
NCT02914938 | Phase I | zandelisib Rituximab + zandelisib | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Terminated | USA | CHE | 0 |
NCT02924402 | Phase I | XmAb13676 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies | Completed | USA | GBR | FRA | 1 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02966756 | Phase II | Venetoclax | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting | NZL | AUS | 2 |
NCT03010358 | Phase Ib/II | Entospletinib + Obinutuzumab | Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03088878 | Phase Ib/II | Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib | A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | Completed | USA | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03204188 | Phase II | Fludarabine + Ibrutinib + Pembrolizumab | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03331198 | Phase Ib/II | Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Recruiting | USA | CAN | 0 |
NCT03336333 | Phase III | Venetoclax + Zanubrutinib Zanubrutinib Bendamustine + Rituximab | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA) | Active, not recruiting | USA | SWE | POL | NZL | ITA | GBR | FRA | ESP | CZE | BEL | AUT | AUS | 3 |
NCT03370185 | Phase II | Duvelisib | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | Withdrawn | USA | 0 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03406156 | Phase III | Bendamustine + Obinutuzumab Obinutuzumab + Venetoclax Bendamustine | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy | Completed | USA | 0 |
NCT03422393 | Phase I | Ibrutinib + Venetoclax Venetoclax | Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib | Active, not recruiting | USA | 0 |
NCT03454165 | Phase I | BNC105P + Ibrutinib | A Study of BNC105P Combined With Ibrutinib | Completed | USA | 0 |
NCT03462719 | Phase III | Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ISR | GBR | FRA | ESP | DNK | CZE | CAN | BEL | 1 |
NCT03479268 | Phase I | Ibrutinib + MLN4924 | Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03492125 | Phase I | MS-553 | A Study Of The Selective PKC-beta Inhibitor MS- 553 | Terminated | USA | 0 |
NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Active, not recruiting | USA | 0 |
NCT03516617 | Phase II | Acalabrutinib Acalabrutinib + Obinutuzumab | Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT03534323 | Phase Ib/II | Duvelisib + Venetoclax | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL | Active, not recruiting | USA | 0 |
NCT03547115 | Phase I | Voruciclib | A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies | Recruiting | USA | 0 |
NCT03557619 | Phase I | Ethinylestradiol + Levonorgestrel + Venetoclax | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies | Recruiting | USA | AUS | 0 |
NCT03572634 | Phase Ib/II | Dubermatinib Dubermatinib + Ibrutinib | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | Terminated | USA | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03580928 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO) | Active, not recruiting | USA | 0 |
NCT03625037 | Phase Ib/II | Epcoritamab-bysp | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1) | Active, not recruiting | USA | SWE | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUS | 2 |
NCT03701282 | Phase III | Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab + Venetoclax | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | Active, not recruiting | USA | ISR | 0 |
NCT03711578 | Phase II | Tenalisib | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | USA | AUS | 0 |
NCT03734016 | Phase III | Ibrutinib Zanubrutinib | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | Completed | USA | TUR | SWE | POL | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 1 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03759184 | Phase I | Obinutuzumab + rhIL-15 | Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | Terminated | USA | 0 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | DNK | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | 0 |
NCT03788291 | Phase II | Acalabrutinib + Rituximab | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | Completed | USA | 0 |
NCT03824483 | Phase II | Obinutuzumab + Venetoclax + Zanubrutinib | Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | Recruiting | USA | 0 |
NCT03828448 | Phase II | Ublituximab + Umbralisib | Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma | Terminated | USA | 0 |
NCT03884972 | Phase I | Trabectedin + Venetoclax | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor | Withdrawn | USA | 0 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT03960840 | Phase I | Ibrutinib + YTB323 YTB323 | CD19-specific CAR-T Cells in CLL/SLL and DLBCL | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT03961672 | Phase II | Duvelisib | Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT04007029 | Phase I | Tocilizumab Anti-CD19-CD20 CAR T cells + Cyclophosphamide + Fludarabine | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04014205 | Phase I | Orelabrutinib | A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies | Active, not recruiting | USA | POL | ISR | 1 |
NCT04018248 | Phase I | BR101801 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | Active, not recruiting | USA | 1 |
NCT04038359 | Phase II | Duvelisib | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | Completed | USA | POL | ITA | GBR | DEU | CZE | 2 |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04116437 | Phase II | Zanubrutinib | A Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment With Ibrutinib | Recruiting | USA | 0 |
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04160195 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT04169737 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04209621 | Phase II | Duvelisib + Ibrutinib | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT04230304 | Phase II | Daratumumab + Ibrutinib | Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study | Active, not recruiting | USA | 0 |
NCT04269902 | Phase III | Obinutuzumab + Venetoclax | Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL/SLL Study | Recruiting | USA | CAN | 0 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04419519 | Phase II | Venetoclax | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | Recruiting | USA | 0 |
NCT04434196 | Phase I | CC-99282 + Obinutuzumab | A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Completed | USA | ESP | CAN | AUT | 0 |
NCT04458610 | Phase II | Rituximab + Zanubrutinib | BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient | Recruiting | USA | 0 |
NCT04501939 | Phase II | Cirmtuzumab + Venetoclax | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax (Venetoclax) | Active, not recruiting | USA | 0 |
NCT04505254 | Phase II | Acalabrutinib + Obinutuzumab | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ISR | GBR | FRA | ESP | AUS | 2 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04560322 | Phase II | Obinutuzumab + Venetoclax Ibrutinib + Obinutuzumab + Venetoclax | Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL | Recruiting | USA | 0 |
NCT04578600 | Phase I | Azacitidine + Lenalidomide + Obinutuzumab | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT04588922 | Phase I | GFH009 | A Study of GFH009 in Patients With Hematologic Malignancies | Recruiting | USA | 1 |
NCT04623541 | Phase Ib/II | Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) | Recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 0 |
NCT04624633 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | AU2 In Relapsed and Untreated CLL | Active, not recruiting | USA | 0 |
NCT04657094 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT04659044 | Phase II | Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax Rituximab Hyaluronidase + Venetoclax | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Terminated | USA | 0 |
NCT04660045 | Phase II | Acalabrutinib | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Withdrawn | USA | 0 |
NCT04665115 | Phase II | Ibrutinib | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | Withdrawn | USA | 0 |
NCT04666038 | Phase III | Idelalisib + Rituximab Pirtobrutinib Bendamustine + Rituximab | Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL | Active, not recruiting | USA | TUR | POL | ITA | ISR | IRL | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
NCT04685915 | Phase II | Copanlisib + Ibrutinib | Copanlisib Plus Ibrutinib in R/R CLL | Withdrawn | 0 | |
NCT04704323 | Phase I | CAP-100 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Recruiting | USA | ESP | 0 |
NCT04722172 | Phase II | Acalabrutinib + Obinutuzumab | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Active, not recruiting | USA | 0 |
NCT04728893 | Phase II | ARQ 531 | Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Recruiting | USA | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 3 |
NCT04758975 | Phase II | Rituximab + Venetoclax Ibrutinib + Rituximab + Venetoclax | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE) | Recruiting | ITA | 0 |
NCT04763083 | Phase Ib/II | NVG-111 | First in Human Study of NVG-111 in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma | Recruiting | GBR | 0 |
NCT04771507 | Phase Ib/II | Ibrutinib | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (IbruOnOff) | Recruiting | SWE | NOR | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04781855 | Phase I | Ibrutinib + Ipilimumab Ibrutinib + Ipilimumab + Nivolumab | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation | Active, not recruiting | USA | 0 |
NCT04809467 | Phase Ib/II | Parsaclisib + Tafasitamab-cxix | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04843904 | Phase I | Obinutuzumab + Rituximab + Venetoclax | Safe Accelerated Venetoclax Escalation in CLL (SAVE) | Recruiting | USA | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Unknown status | AUS | 1 |
NCT04892277 | Phase I | Bendamustine IC19/1563 Cyclophosphamide + Fludarabine | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT04908228 | Phase II | Ibrutinib + Obinutuzumab | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT) | Recruiting | ITA | 0 |
NCT04941716 | Phase II | Acalabrutinib + Venetoclax | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04965493 | Phase III | Rituximab + Venetoclax Pirtobrutinib + Rituximab + Venetoclax | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) | Active, not recruiting | USA | SWE | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BEL | AUS | 6 |
NCT04981912 | Phase I | Methylprednisolone + Rituximab | Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients | Active, not recruiting | USA | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | TUR | SWE | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 3 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05023980 | Phase III | Pirtobrutinib Bendamustine + Rituximab | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313) | Active, not recruiting | USA | ROU | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | BRA | BGR | AUT | AUS | 6 |
NCT05057494 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Venetoclax | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC) | Active, not recruiting | USA | POL | HUN | FRA | ESP | CZE | AUS | 0 |
NCT05069051 | Phase II | Belimumab + Rituximab + Venetoclax | Belimumab in Patients With Chronic Lymphocytic Leukemia (BeliVeR) | Recruiting | DEU | 0 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | NLD | GBR | 0 |
NCT05144347 | Phase I | XL114 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT05153330 | Phase I | BMF-219 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL With KMT2A/ MLL1r, NPM1 and Other Mutations | Recruiting | USA | NLD | ITA | GRC | ESP | 0 |
NCT05168930 | Phase II | Venetoclax + Zanubrutinib | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | Recruiting | USA | 0 |
NCT05172700 | Expanded access | Pirtobrutinib | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | Available | 0 | |
NCT05197192 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | A Prospective, Open-label, Multicentre, Randomized, Phase-3-trial of Acalabrutinib, Obinutuzumab and Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk Chronic Lymphatic Leukemia | Recruiting | DEU | 0 |
NCT05244070 | Phase I | BMS-986403 + Cytarabine + Fludarabine | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | ESP | 0 |
NCT05254743 | Phase III | Ibrutinib Pirtobrutinib | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT05256641 | Phase Ib/II | Acalabrutinib | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Recruiting | USA | 0 |
NCT05275504 | Phase I | TT-01488 | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | Unknown status | USA | 0 |
NCT05336812 | Phase II | Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05360238 | Phase Ib/II | MB-106 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Terminated | USA | 0 |
NCT05388006 | Phase II | Acalabrutinib + Durvalumab + Venetoclax | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT05405309 | Phase Ib/II | Olaparib + RP-3500 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) | Terminated | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05536349 | Phase II | Obinutuzumab + Pirtobrutinib + Venetoclax | Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | Recruiting | USA | 0 |
NCT05602363 | Phase I | AS-1763 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05624554 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | Recruiting | USA | TUR | ROU | POL | LTU | HUN | DNK | BRA | BGR | AUS | 11 |
NCT05650723 | Phase II | Venetoclax + Zanubrutinib Obinutuzumab + Venetoclax + Zanubrutinib | Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab | Recruiting | USA | 0 |
NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT05665530 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | POL | ITA | GBR | FRA | DEU | CHE | CAN | AUS | 1 |
NCT05677919 | Phase II | Pirtobrutinib + Venetoclax | Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia, MIRACLE Study | Recruiting | USA | 0 |
NCT05694312 | Phase II | Ibrutinib | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | Recruiting | ITA | 0 |
NCT05702853 | Phase Ib/II | CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | Recruiting | USA | 0 |
NCT05718869 | Phase II | Tafasitamab-cxix + Zanubrutinib | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | Recruiting | USA | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05797233 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05947851 | Phase III | Rituximab + Venetoclax ARQ 531 + Venetoclax | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) | Recruiting | USA | TUR | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 4 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05963074 | Phase II | Ibrutinib Ibrutinib + Venetoclax | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) | Recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | CAN | 0 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT05967416 | Phase I | SIRPant-M | Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT05971251 | Phase I | Acalabrutinib + Loncastuximab tesirine-lpyl | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT05983965 | Phase I | Tazemetostat Acalabrutinib + Tazemetostat | Study of Tazemetostat in Lymphoid Malignancies | Recruiting | USA | 0 |
NCT06136559 | Phase III | Ibrutinib ARQ 531 Acalabrutinib | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | ISR | GRC | GBR | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | 11 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT06205290 | Phase III | Idelalisib + Rituximab Lisocabtagene maraleucel Cyclophosphamide + Fludarabine Bendamustine + Rituximab | A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies | Withdrawn | USA | SWE | NOR | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | 0 |
NCT06291220 | Phase I | Obinutuzumab ABBV-453 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Recruiting | USA | ISR | DEU | AUS | 0 |
NCT06333262 | Phase II | Obinutuzumab + Pirtobrutinib Pirtobrutinib | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | Recruiting | USA | 0 |
NCT06364423 | Phase Ib/II | Hu19-CD828Z T cells + Rituximab Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06428019 | Phase III | Obinutuzumab + Venetoclax Acalabrutinib + Venetoclax | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | 1 |
NCT06466122 | Phase II | Pirtobrutinib + Venetoclax | Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | Recruiting | USA | 0 |
NCT06520098 | Phase II | Ibrutinib Zanubrutinib Ibrutinib + Venetoclax Venetoclax + Zanubrutinib Acalabrutinib Acalabrutinib + Venetoclax | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Benefit VA) | Not yet recruiting | USA | 0 |
NCT06542250 | Phase Ib/II | AZD5492 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. (TITANium) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | CAN | AUS | 1 |